2.07 USD
↘ 0.01 (0.24%)LIVE (AS OF 03:21 PM EDT)
Grace Therapeutics, Inc. Common Stock
GRCENASDAQ • USD
Market: OPEN
Shares of Grace Therapeutics, Inc. Common Stock (GRCE) are trading at $2.07. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, GRCE appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Oct 2, 2026.
Open?$2.04
High?$2.08
Low?$2.00
Prev. Close?$2.07
Volume?66.9K
Avg. Volume?136.0K
VWAP?$2.04
Rel. Volume?0.49x
Bid / Ask
Bid?$2.06 × 200
Ask?$2.39 × 100
Spread?$0.33
Midpoint?$2.23
Valuation & Ratios
Market Cap?43.5M
Shares Out?21.0M
Float?15.1M
Float %?71.6%
P/E Ratio?N/A
P/B Ratio?0.90
EPS?-$0.96
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Address
103 CARNEGIE CENTER
PRINCETON, NJ 08540
Phone: 609-322-1602
PRINCETON, NJ 08540
Phone: 609-322-1602
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?29
Piotroski F-Score?0/9Weak
Altman Z-Score?5.94Safe
Confidence?36%Very Low
Short InterestHigh
Short % of Float?11.72%High
Short Interest?1.8M
Days to Cover?8.6
Free Float15.1M
Avg Daily Volume206.1K
Settlement Date2026-09-15
Financial Health
Current Ratio?11.47Strong
Quick Ratio?11.47Strong
Cash Ratio?11.00Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.90CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-2.9CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-41.9%WEAK▾
S&P3
ROA?-40.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-10289000
Enterprise Value?$29.8M
Fundamentals ratios updated end of day